Given that podocyte dysfunction is a common feature of most proteinuric forms of kidney disease, understanding the mechanisms of podocyte injury, and how the effectors of mechanisms might be modulated for therapeutic benefit, we believe that these experiments provide new clues as to how Rho-mediated injury might be modulated. The gene discussed is RHO; the disease is kidney disorder.